| Steven W Dipillo, MD | |
|
325b King St, Northampton, MA 01060-2370 | |
| (413) 584-1588 | |
| (413) 585-0821 |
| Full Name | Steven W Dipillo |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 35 Years |
| Location | 325b King St, Northampton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104807122 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 73113 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South Shore Hospital | South weymouth, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atrius Health Inc | 4789588641 | 1116 |
| So Shore Cardiology Pc | 9335213446 | 14 |
News Archive
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.
"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
In a new report that bucks the concerns raised by the Food and Drug Administration, a Boston University School of Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much safer than real cigarettes and show promise in the fight against tobacco-related diseases and death.
Nine new alluring, body-contouring and eco-friendly tanning beds make up a new line of commercial tanning beds that begin shipping soon from tanning equipment leader ETS Tan.
› Verified 1 days ago
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.
"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
In a new report that bucks the concerns raised by the Food and Drug Administration, a Boston University School of Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much safer than real cigarettes and show promise in the fight against tobacco-related diseases and death.
Nine new alluring, body-contouring and eco-friendly tanning beds make up a new line of commercial tanning beds that begin shipping soon from tanning equipment leader ETS Tan.
› Verified 1 days ago
| Entity Name | Cooley Dickinson Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477596310 PECOS PAC ID: 8123090560 Enrollment ID: O20040806001098 |
News Archive
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.
"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
In a new report that bucks the concerns raised by the Food and Drug Administration, a Boston University School of Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much safer than real cigarettes and show promise in the fight against tobacco-related diseases and death.
Nine new alluring, body-contouring and eco-friendly tanning beds make up a new line of commercial tanning beds that begin shipping soon from tanning equipment leader ETS Tan.
› Verified 1 days ago
| Entity Name | So Shore Cardiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497895213 PECOS PAC ID: 9335213446 Enrollment ID: O20080807000577 |
News Archive
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.
"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
In a new report that bucks the concerns raised by the Food and Drug Administration, a Boston University School of Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much safer than real cigarettes and show promise in the fight against tobacco-related diseases and death.
Nine new alluring, body-contouring and eco-friendly tanning beds make up a new line of commercial tanning beds that begin shipping soon from tanning equipment leader ETS Tan.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven W Dipillo, MD 280 Chestnut St, 2nd Floor, Springfield, MA 01199-1001 Ph: (413) 794-5700 | Steven W Dipillo, MD 325b King St, Northampton, MA 01060-2370 Ph: (413) 584-1588 |
News Archive
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.
"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
In a new report that bucks the concerns raised by the Food and Drug Administration, a Boston University School of Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much safer than real cigarettes and show promise in the fight against tobacco-related diseases and death.
Nine new alluring, body-contouring and eco-friendly tanning beds make up a new line of commercial tanning beds that begin shipping soon from tanning equipment leader ETS Tan.
› Verified 1 days ago
Alys Malcolm, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Locust St, Northampton, MA 01060 Phone: 413-582-2900 Fax: 413-923-9322 | |
Kyle A. Cooper, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 325b King St, Northampton, MA 01060 Phone: 413-794-2273 Fax: 413-387-4136 | |
Heather Wark, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 548 Elm St, Northampton, MA 01060 Phone: 413-586-3150 Fax: 413-774-7049 | |
Dr. Howard Douglas Klein, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 421 N Main St, Northampton, MA 01060 Phone: 413-584-4040 | |
Dr. Julio A. Miranda, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Locust St, Northampton, MA 01060 Phone: 413-582-2114 Fax: 413-582-4968 | |
Dr. Andrew F. Hall, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 264 Elm St, Suite 12, Northampton, MA 01060 Phone: 413-586-1100 Fax: 413-584-7062 |